Tags

Type your tag names separated by a space and hit enter

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
BJU Int. 2010 Feb; 105(4):502-7.BI

Abstract

OBJECTIVE

To determine, by post hoc analysis, the effects of tadalafil (a long-acting phosphodiesterase 5 inhibitor) on peak urinary flow (Q(max)), bladder capacity, voiding efficiency and the obstructive symptoms of benign prostatic hyperplasia (BPH) in men with lower urinary tract symptoms secondary to BPH (BPH-LUTS), compared with placebo.

PATIENTS AND METHODS

After a 4-week placebo run-in period, 1058 men with BPH-LUTS were randomly allocated to receive once daily treatment with placebo or tadalafil (2.5, 5, 10, or 20 mg) for 12 weeks. Uroflowmetry, postvoid residual volume (PVR), and BPH symptom score measurements were assessed throughout the trial.

RESULTS

Increases in Q(max) were numerically greater for tadalafil (2.5, 5, 10, and 20 mg with percentage changes of 15%, 16%, 17%, 22%, respectively) vs placebo (12%), but did not reach statistical significance. Age, baseline Q(max), erectile dysfunction history, sexual activity, and previous alpha-blocker therapy significantly influenced the Q(max) response. Tadalafil was not associated with significant changes in PVR. Tadalafil had its greatest effects on bladder capacity and voiding efficiency in men with a Q(max) of <10 mL/s at baseline, but these changes were not significantly different from placebo responses. Tadalafil treatment significantly improved the IPSS obstructive subscores (tadalafil 2.5, 5, 10, 20 mg with percentage changes of 24%, 31%, 33%, 33%, respectively) vs placebo (13%).

CONCLUSIONS

Once daily tadalafil did not significantly change Q(max) or voiding efficiency compared with placebo in men with BPH-LUTS, although there were dose-dependent improvements. No subgroups were identified where tadalafil or placebo treatment had a deleterious effect on Q(max). Despite these minimal changes in uroflowmetric measures, tadalafil was associated with clinically meaningful and statistically significant improvements in the obstructive symptoms of BPH.

Authors+Show Affiliations

University of Texas Southwestern Medical Center, Dallas, TX, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

19732051

Citation

Roehrborn, Claus G., et al. "Changes in Peak Urinary Flow and Voiding Efficiency in Men With Signs and Symptoms of Benign Prostatic Hyperplasia During once Daily Tadalafil Treatment." BJU International, vol. 105, no. 4, 2010, pp. 502-7.
Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int. 2010;105(4):502-7.
Roehrborn, C. G., Kaminetsky, J. C., Auerbach, S. M., Montelongo, R. M., Elion-Mboussa, A., & Viktrup, L. (2010). Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU International, 105(4), 502-7. https://doi.org/10.1111/j.1464-410X.2009.08822.x
Roehrborn CG, et al. Changes in Peak Urinary Flow and Voiding Efficiency in Men With Signs and Symptoms of Benign Prostatic Hyperplasia During once Daily Tadalafil Treatment. BJU Int. 2010;105(4):502-7. PubMed PMID: 19732051.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. AU - Roehrborn,Claus G, AU - Kaminetsky,Jed C, AU - Auerbach,Stephen M, AU - Montelongo,Rafael Martínez, AU - Elion-Mboussa,Albert, AU - Viktrup,Lars, Y1 - 2009/09/03/ PY - 2009/9/8/entrez PY - 2009/9/8/pubmed PY - 2010/3/27/medline SP - 502 EP - 7 JF - BJU international JO - BJU Int. VL - 105 IS - 4 N2 - OBJECTIVE: To determine, by post hoc analysis, the effects of tadalafil (a long-acting phosphodiesterase 5 inhibitor) on peak urinary flow (Q(max)), bladder capacity, voiding efficiency and the obstructive symptoms of benign prostatic hyperplasia (BPH) in men with lower urinary tract symptoms secondary to BPH (BPH-LUTS), compared with placebo. PATIENTS AND METHODS: After a 4-week placebo run-in period, 1058 men with BPH-LUTS were randomly allocated to receive once daily treatment with placebo or tadalafil (2.5, 5, 10, or 20 mg) for 12 weeks. Uroflowmetry, postvoid residual volume (PVR), and BPH symptom score measurements were assessed throughout the trial. RESULTS: Increases in Q(max) were numerically greater for tadalafil (2.5, 5, 10, and 20 mg with percentage changes of 15%, 16%, 17%, 22%, respectively) vs placebo (12%), but did not reach statistical significance. Age, baseline Q(max), erectile dysfunction history, sexual activity, and previous alpha-blocker therapy significantly influenced the Q(max) response. Tadalafil was not associated with significant changes in PVR. Tadalafil had its greatest effects on bladder capacity and voiding efficiency in men with a Q(max) of <10 mL/s at baseline, but these changes were not significantly different from placebo responses. Tadalafil treatment significantly improved the IPSS obstructive subscores (tadalafil 2.5, 5, 10, 20 mg with percentage changes of 24%, 31%, 33%, 33%, respectively) vs placebo (13%). CONCLUSIONS: Once daily tadalafil did not significantly change Q(max) or voiding efficiency compared with placebo in men with BPH-LUTS, although there were dose-dependent improvements. No subgroups were identified where tadalafil or placebo treatment had a deleterious effect on Q(max). Despite these minimal changes in uroflowmetric measures, tadalafil was associated with clinically meaningful and statistically significant improvements in the obstructive symptoms of BPH. SN - 1464-410X UR - https://www.unboundmedicine.com/medline/citation/19732051/Changes_in_peak_urinary_flow_and_voiding_efficiency_in_men_with_signs_and_symptoms_of_benign_prostatic_hyperplasia_during_once_daily_tadalafil_treatment_ L2 - https://doi.org/10.1111/j.1464-410X.2009.08822.x DB - PRIME DP - Unbound Medicine ER -